COLUMBUS, Ohio – A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. More »
Neuroblastoma is an embryonal tumor of the sympathetic nervous system and the most common extracranial tumor of childhood. By sequencing More »
Long non-coding RNAs (lncRNAs, pseudogenes and circRNAs) have recently come into light as powerful players in cancer pathogenesis and it More »
The study analysed experiments carried out on six different species and identified almost 2,500 IncRNAs that were not in the More »
Prostate cancer is one of the leading causes of mortality among US males. There is an urgent unmet need to develop sensitive and specific biomarkers for the early detection of prostate cancer to reduce overtreatment and accompanying morbidity. Researchers at the Sanford-Burnham Medical Research Institute identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples (Gleason score >6.0) and compared them with matched normal (healthy) tissues. Interestingly, these markers were also successfully detected in patient urine samples and were found to be up-regulated when compared with normal (healthy) urine. AK024556 (SPRY4-IT1) was highly up-regulated in human prostate cancer cell line PC3 but not in LNCaP, and siRNA knockdown of SPRY4-IT1 in PC3 cells inhibited cell proliferation and invasion and increased cell apoptosis. Chromogenic in situ hybridization assay was developed to detect long noncoding RNAs in primary prostatic adenocarcinoma tissue samples, paving the way for clinical diagnostics. The researchers believe that these results will set the stage for more extensive studies to develop novel long noncoding RNA-based diagnostic assays for early prostate cancer detection and will help to distinguish benign prostate cancer from precancerous lesions.
- Lee B, Mazar J, Aftab MN, Qi F, Shelley J, Li JL, Govindarajan S, Valerio F, Rivera I, Thurn T, Tran TA, Kameh D, Patel V, Perera RJ. (2014) Long noncoding RNAs as putative biomarkers for prostate cancer detection. J Mol Diagn 16(6):615-26. [abstract]
COLUMBUS, Ohio – A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML). AML occurs mainly in older patients and has a three-year survival rate of 5 to 15 percent.
Location: Grenoble, France
Staff Category: Postdoctoral Fellow
Contract Duration: 2 years
Reference Number: GR_00072
Closing Date: 4 January 2015
The European Molecular Biology Laboratory (EMBL) is one of the highest ranked scientific research organisations in the world. The Headquarters Laboratory is located in Heidelberg (Germany), with additional sites in Grenoble (France), Hamburg (Germany), Hinxton (UK) and Monterotondo (Italy).
EMBL is seeking to recruit a postdoctoral researcher to join the group of Marco Marcia at EMBL Grenoble. EMBL is a leading international research organization with a collaborative atmosphere. We are seeking to recruit an outstanding candidate with a strong interest in applying structural biology approaches to important biological problems. We focus on ribonucleoproteins formed by long non-coding RNAs and involved in transcription regulation.
Qualifications and Experience
The successful applicant should hold a Ph.D. and have a solid background in biochemical analysis of protein and/or RNA complexes. Experience in single particle cryo-electron microscopy and/or X-ray crystallography would be an advantage. The laboratory has excellent access to state-of-the-art equipment including the ESRF synchrotron and a Tecnai
F20 Polara equipped with K2 direct electron detector. We welcome applications from candidates that are interested in working at the interface of cryoEM and X-ray crystallography. Motivation to work in a multidisciplinary and international environment is fundamental to this position.
Please apply online through www.embl.org/jobs
EMBL is an inclusive, equal opportunity employer offering attractive conditions and benefits appropriate to an international research organisation. Please note that appointments on fixed term contracts can be renewed, depending on circumstances at the time of the review.
from Beta Boston by Dennis Keohane
RaNA Therapeutics, a company that is using a novel approach to fight disease using RNA, is coming out of stealth today and announcing that Ronald Renaud Jr. will be the company’s new chief executive officer.
Founded at the end of 2011 using technology developed by Jeannie Lee, an investigator at the Howard Hughes Medical Institute at Massachusetts General Hospital, RaNA uses long noncoding RNA, which was once called “junk RNA” because it was thought to be useless, to develop treatments for diseases that have often been difficult to fight. Research into noncoding RNA been instrumental in the burgeoning field of epigenetics, which considers how chemical tags that operate outside of our DNA help genes express themselves.
Long noncoding RNAs (lncRNAs) have been widely regarded as crucial regulators in various biological processes involved in carcinogenesis. However, the comprehensive lncRNA expression signature in colorectal cancer remains fully unknown. Researchers at Nanjing Medical University performed a high throughput microarray assay to detect lncRNA expression profile in three paired human colorectal cancer tissues and their adjacent normal tissues. Additional 90 paired colorectal samples were collected to verify differently expression levels of two selected lncRNAs using q-RT-PCR assay. Bioinformatic approaches were performed to explore into the functions of these differently expressed lncRNAs.
Microarray assay showed a series of lncRNAs were differently expressed in colorectal cancer. Two of the lncRNAs, HOTAIR and a novel lncRNA, lncRNA-422 were confirmed in more samples (P=0.015 for HOTAIR and P=0.027 for lncRNA-422, respectively). GSEA indicated that gene sets most correlated with them were those named up-regulated in KRAS-over, down-regulated in JAK2-knockout, down-regulated in PDGF-over and down-regulated in TBK1-knockout, all of which were cancer-related. Subsequently, GO analyses of most significantly correlated coding genes of HOTAIR and lncRNA-422 showed that these two lncRNAs may participate in carcinogenesis by regulating protein coding genes involved in special biological process relevant to cancer.
This study demonstrated that different lncRNA expression patterns were involved in colorectal cancer. Besides, HOTAIR and lncRNA-422 were identified to participate in colorectal cancer. Further studies into biological mechanisms of differently expressed lncRNAs identified in this study will help to provide new perspective in colorectal cancer pathogenesis.
- Xue Y, Ma G, Gu D, Zhu L, Hua Q, Du M, Chu H, Tong N, Chen J, Zhang Z, Wang M. (2014) Genome-wide analysis of long noncoding RNA signature in human colorectal cancer. Gene [Epub ahead of print]. [abstract]